CSF2 and posterior cortical atrophy: The findings indicated that pTVG-HP did not result in a statistically significant improvement in the two-year MFS for patients with desmoplasia-sensitive PCa, with the MFS recorded at 42.7% for the vaccine group compared to 41.8% for the GM-CSF alone group.